Siemens Healthineers Launches Six AI Imaging Systems as Shares Tumble to 52-Week Low

FDA clears six AI-powered interventional imaging systems, but Siemens Healthineers stock hits 52-week low as diagnostics struggles and lowered guidance dampen sentiment.

Siemens Healthineers secured U.S. regulatory clearance for six new interventional imaging systems powered by its Optiq AI Imaging Chain, yet the milestone barely stirred a market fixated on the company’s struggling diagnostics business. The FDA approvals cover floor, biplane, ceiling, and Pheno variants of the Artis Vision platform, plus floor configurations of the Artis icono.explore and Artis genio platforms, all featuring deep-learning-based noise reduction for fluoroscopy and digital subtraction angiography. The package also includes the syngo DynaCT MORE 3D application for reducing motion artifacts and a renewed CDC certification for the Atellica IM Testosterone II assay in diagnostics.

The stock, however, closed Friday at €33.34 — exactly its 52-week low and roughly 25% below the start of the year. The session saw a further 1.32% decline that brought the share near the €33.50 mark before hitting the deeper trough. Year to date, the equity has shed 24.39% in a market where geopolitical tensions and rising oil prices have curbed risk appetite across German healthcare and life sciences names. The median analyst price target of €49.78 suggests a potential upside of nearly one-third from current levels, but near-term sentiment remains deeply skeptical.

Analysts are split on the path forward. Jefferies retains a “Buy” rating with a €50 target, acknowledging that imaging and Varian (the oncology unit) posted strong comparable growth of 6.1% and 7.5%, respectively, in the fiscal second quarter. The diagnostics segment, however, disappointed, and a reassessment of the shares is unlikely before late in the second half, according to the broker. Deutsche Bank Research strikes a more cautious tone: it holds at “Hold” and cut its price target from €42 to €38. Analyst Falko Friedrichs argues that above-average share performance will remain challenging unless the company delivers a clear acceleration in growth and margins. The consensus for fiscal 2027 earnings per share, he adds, still looks ambitious.

The underlying numbers illustrate the headwinds. Reported group revenue fell to around €5.68 billion in the second quarter, with diluted EPS at €0.45. Management responded by lowering its fiscal 2026 outlook: revenue growth is now expected at 4.5% to 5.0%, and adjusted EPS in a range of €2.20 to €2.30. That compares with a market consensus of roughly €2.26 for the year, leaving little room for error. The main culprit is diagnostics, where structural weakness in China is weighing heavily — a drag that will be the key variable when the company reports third-quarter results in July.

Beyond the near-term earnings calendar, a planned spin-off from Siemens AG is set for a shareholder vote at the ordinary annual general meetings of both companies in early 2027. Until then, investors will watch whether the diagnostics slump in China proves temporary or entrenched, and whether the new AI imaging suite can command enough attention to shift the narrative. For now, the €33.34 level stands as the floor; a break below it would intensify the debate over earnings trajectories and valuation.